Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Tofaris

    - PMLiVE

    Mission Therapeutics advances Parkinson’s disease candidate

    The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

    - PMLiVE

    PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

    The US-based company develops light-based therapies for neurodegenerative conditions

    - PMLiVE

    TRIMTECH Therapeutics establishes Scientific Advisory Board

    Alessio Ciulli has been appointed as Chair of the board

    - PMLiVE

    Roche shares promising data from Alzheimer’s disease development portfolio

    The company is planning to initiate phase 3 studies of trontinemab in early AD this year

    - PMLiVE

    UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

    It is hoped that the test could be available for widespread UK use in the coming years

    - PMLiVE

    GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn

    The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform

    - PMLiVE

    Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    GSK to explore link between Shingrix and dementia risk in new UK research collaboration

    More than 55 million people worldwide are currently living with the neurodegenerative disease

    - PMLiVE

    UK drug repurposing study identifies several potential dementia treatments

    An estimated 982,000 people in the UK are currently living with the neurodegenerative disease

    - PMLiVE

    Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies

    The neurodegenerative disease affects approximately 30,000 people in the US

    - PMLiVE

    GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

    The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

    - PMLiVE

    Researchers develop new approach to target cells affected by motor neurone disease

    The technique could lead to safer and more effective gene therapies for the neurodegenerative disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links